• Many novel adjuvants are available for rational selection with HIV vaccines. • Inducing protective and durable immunity to HIV presents unique challenges. • Understanding immune correlates of HIV vaccine protection can guide adjuvant selection. • An NIAID workshop solicited suggestions to advance adjuvants selection for HIV vaccines. This report summarizes the highlights of a workshop convened by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), on April 4–5, 2022, to provide a discussion forum for sharing insights on the current status, key challenges, and next steps to advance the current landscape of promising adjuvants in preclinical and clinical human immunodeficiency virus (HIV) vaccine studies. A key goal was to solicit and share recommendations on scientific, regulatory, and operational guidelines for bridging the gaps in rational selection, access, and formulation of clinically relevant adjuvants for HIV vaccine candidates. The NIAID Vaccine Adjuvant Program working group remains committed to accentuate promising adjuvants and nurturing collaborations between adjuvant and HIV vaccine developers. [ABSTRACT FROM AUTHOR]